A. The sitagliptin will inhibit liraglutide from eliciting its full effect. B. The sitagliptin will displace bound liraglutide from albumin, thus increasing the percent of free liraglutide and therefore increasing the likelihood of toxic effects. C. The possibility of pancreatitis will be increased with combined use. D. Both medications exhibit effects on the incretin system, thus providing little added efficacy when combined. E. Unsure

A. Discontinue the glipizide. B. Decrease the dose of metformin. C. Add metoclopramide to mitigate possible gastroparesis. D. Add ondansetron to mitigate possible nausea. E. Unsure

A. Benefit was only gained by patients who had previously experienced a major adverse cardiovascular event. B. The studies predominately included patients who required secondary risk prevention. C. Most people with type 2 diabetes have ASCVD. D. Patients without ASCVD were excluded from these cardiovascular outcome trials. E. Unsure